NCT00310817 - Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. | Biotech Hunter

Enrollment

623

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions

Meningococcal Meningitis

Interventions

BIOLOGICAL

MenACWY-CRM conjugate vaccine, adjuvanted

BIOLOGICAL

MenACWY polysaccharide vaccine

BIOLOGICAL

MenACWY-CRM conjugate vaccine, unadjuvanted

Trial Locations (2)

University of Tampere Medical School, Tampere

Oddz. Neuroinfekcji, Szpital Jana Pawla II, Krakow, Samodzielny ZOZ, Lubartów